Patents by Inventor Gary Avonn Cain

Gary Avonn Cain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HT7 receptor antagonists
    Patent number: 6486173
    Abstract: The present invention relates to compounds having pharmacological activity toward the 5-HT7 receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: November 26, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Gary Avonn Cain, John Francis McElroy
  • Arylamino fused pyridines
    Patent number: 6448261
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • 5-HT7 receptor antagonists
    Patent number: 6239143
    Abstract: The present invention relates to compounds having pharmacological activity toward the 5-HT7 receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 29, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Gary Avonn Cain, John Francis McElroy
  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Arylamino fused pyrimidines
    Patent number: 6107300
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Isoxazoline and isoxazole fibrinogen receptor antagonists
    Patent number: 5849736
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
    Patent number: 5739163
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: April 14, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Gary Avonn Cain, Charles Joseph Eyermann, Richard Eric Olson